# Abbott Laboratories (ABT) Q2 2026 earnings

Results filed 2026-07-16 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/abt/2026-q2/
Press release and exhibits: https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/0001628280-26-048377-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Abbott reported second-quarter sales growth of 13.0 percent, comparable sales growth of 4.8 percent, GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31.

Abbott's second-quarter sales rose 13.0 percent to $12,593 million, helped by the March 23 acquisition of Exact Sciences. On a comparable basis, which includes Exact's sales in both years, growth was 4.8 percent. Medical Devices grew 8.4 percent comparable, led by Electrophysiology. Nutrition fell 3.6 percent. GAAP diluted EPS was $0.53, down from $1.01, on higher amortization, interest and tax charges and a $385 million legal reserve. Adjusted EPS was $1.31, up 4.0 percent.
Management reaffirmed full-year comparable sales growth of 6.5% to 7.5% and raised adjusted EPS guidance to $5.45 to $5.60 from $5.38 to $5.58. Third-quarter adjusted EPS is guided to $1.38 to $1.46. The CEO expects accelerating sales and earnings growth in the second half. The main tension is that first-half comparable growth was 4.3 percent, so the second half must speed up, while Nutrition remains weak and acquisition costs weigh on GAAP results.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Net sales | $12,593 | up 13.0% reported from a year ago; up 4.8% comparable | GAAP |
| Net earnings | $928 | down 47.8% from a year ago | GAAP |
| Diluted EPS | $0.53 | vs. $1.01 a year ago | GAAP |
| Adjusted diluted EPS | $1.31 | up 4.0% from a year ago | non-GAAP |
| Operating earnings | 1,693 | down 17.5% from a year ago | GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Nutrition | 2,144 | down 3.1% reported; down 3.6% comparable |
| Diagnostics | 3,092 | up 42.3% reported; up 2.9% comparable |
| Established Pharmaceuticals | 1,499 | up 8.4% reported; up 8.7% comparable |
| Medical Devices | 5,853 | up 9.0% reported; up 8.4% comparable |
| Cancer Diagnostics | 919 | up 13.3% comparable |
| Electrophysiology | 861 | up 14.0% reported; up 13.4% comparable |
| Diabetes Care | 2,188 | up 10.5% reported; up 9.0% comparable |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Comparable sales growth | full-year 2026 | 6.5% to 7.5% |
| Adjusted diluted EPS | full-year 2026 | $5.45 to $5.60 |
| Adjusted diluted EPS | third-quarter 2026 | $1.38 to $1.46 |

## Key takeaways

1. **Acquisition drove reported growth well above comparable** Reported sales growth was 13.0 percent versus comparable growth of 4.8 percent. Exact Sciences, acquired on March 23, 2026, added $919 million of Cancer Diagnostics sales.
2. **GAAP earnings fell sharply on deal-related charges** GAAP diluted EPS was $0.53 against $1.01 a year ago. Specified items totaled $0.78 per share, including $385 million for legal reserves tied to an agreed-in-principle settlement.
3. **Medical Devices led with 8.4% comparable growth** Electrophysiology grew 13.4 percent comparable, and Diabetes Care grew 9.0 percent. Continuous glucose monitor sales grew 11.0 percent reported.
4. **Nutrition remains the weak spot** Nutrition sales fell 3.6 percent on a comparable basis on lower volumes and pricing actions taken in the fourth quarter of 2025. Sales rose $127 million sequentially from the first quarter.
5. **Full-year adjusted EPS guidance raised to $5.45-$5.60** The prior range was $5.38 to $5.58, and comparable sales growth guidance of 6.5% to 7.5% was reaffirmed. Third-quarter adjusted EPS is guided to $1.38 to $1.46.

## Questions

**What were Abbott's second-quarter 2026 results?** Sales were $12,593 million, up 13.0 percent reported and 4.8 percent comparable. GAAP diluted EPS was $0.53 and adjusted diluted EPS was $1.31.
**Did Abbott change its 2026 guidance?** It raised full-year adjusted diluted EPS guidance to $5.45 to $5.60 from $5.38 to $5.58. It reaffirmed comparable sales growth of 6.5% to 7.5%.
**Why did GAAP EPS fall to $0.53 from $1.01?** Specified items cost $0.78 per share, including intangible amortization, acquisition charges and a $385 million legal reserve. Interest expense rose to $299 million from $50 million, and the GAAP tax rate was 39.1%.
**Which Abbott businesses performed best and worst?** Medical Devices grew 8.4 percent comparable, led by Electrophysiology at 13.4 percent, and Established Pharmaceuticals grew 8.7 percent. Nutrition declined 3.6 percent comparable.
**What is Abbott guiding for the third quarter?** Abbott projects third-quarter 2026 adjusted diluted EPS of $1.38 to $1.46. It did not provide GAAP guidance.